Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report

[Breast Disease, 41(1) 2022, 255–260, 10.3233/BD-210041] https://content.iospress.com/articles/breast-disease/bd210041

On p. 258, the sentence “Pembrolizumab is a PD-L1 monoclonal antibody.” should read “Pembrolizumab is an anti-PD-1 monoclonal antibody.”